Our Mission

Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research.

Research will Lead us to a CURE

For the 65 million people worldwide with epilepsy, progress is unacceptably slow. Children with uncontrollable seizures frequently face a lifetime of challenges including misunderstandings about epilepsy, discrimination, and other epilepsy-related problems. Mortality rates among people with epilepsy are three times the rate of the general population, and sudden death rates are more than twenty times higher.


  • One in twenty-six Americans will develop epilepsy in their lifetime.
  • An estimated 3.4 million Americans and 65 million people worldwide currently live with epilepsy.
  • Each year at least 200,000 people are diagnosed with epilepsy.
  • In approximately 50% of patients diagnosed with epilepsy, the cause is unknown.
  • Epilepsy affects more people than multiple sclerosis, cerebral palsy, muscular dystrophy and Parkinson’s combined – yet receives fewer federal dollars per patient than each of these.


  • 1989

    After nearly 20 years of no new FDA-approved anti-epileptic drugs, Vigabatrin is introduced, marking the second generation of AEDs.

  • 1993

    FDA and Burroughs Welcome Committee define “Sudden Unexpected Death in Epilepsy, or “SUDEP.”

  • 1997

    Vagus Nerve Stimulator is approved as a non-pharmaceutical treatment option, the first following ketogenic diet and brain surgery.

  • 1998

    CURE is founded by Susan Axelrod to advance the field of epilepsy research in honor of her daughter Lauren.

  • 2003

    108th U.S. Congress passes a resolution recognizing November as National Epilepsy Awareness Month.

  • 2004

    CURE launches SUDEP Signature Research Program. CURE funds first SUDEP research grant to Carl L. Faingold, PhD.

  • 2008

    Purple Day® is celebrated worldwide in support of people with epilepsy for the first time.

  • 2010

    NINDS and CURE develop CWOW concept to advance epilepsy research. Eslicarbazepine is introduced as the first of a new wave of 3rd generation anti-epileptic drugs.

  • 2013

    FDA approves the use of the Responsive Neuropace Stimulator as a non-pharmaceutical treatment option for people with intractable epilepsy.


Read these personal stories to see how research is helping to transform lives for those suffering from epilepsy.

Learn More About Our Work

About CURE

Our Story

Our Research

Signature Programs

Our Research

Grants Awarded

Stay up-to-date with CURE news & epilepsy research discoveries.

Required field missing
Email address invalid